Form 4: Xilio Therapeutics Executive Katarina Luptakova Reports Stock Transactions
SEC Form 4 Filing
Katarina Luptakova, Chief Medical Officer of Xilio Therapeutics, reports the vesting of restricted stock units and grant of stock options.
Summary
- Katarina Luptakova, the Chief Medical Officer of Xilio Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On January 1, 2025, Ms. Luptakova vested 16,625 shares of common stock from restricted stock units (RSUs).
- These RSUs were granted on January 1, 2024, and vest in four equal annual installments starting January 1, 2025, and continuing through January 1, 2028.
- Ms. Luptakova also acquired 200,000 stock options with an exercise price of $0.955 on January 1, 2025.
- These options vest in 48 equal monthly installments beginning February 1, 2025, and continuing through January 1, 2029.
- Following these transactions, Ms. Luptakova directly owns 49,875 restricted stock units and 200,000 stock options.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, with neutral sentiment.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests between management and shareholders. These filings are standard practice for publicly traded companies and their executives.
Comparison to Industry Standards
- Stock option grants and RSU vesting are common forms of executive compensation in the biotechnology industry, used to incentivize performance and align executive interests with shareholder value.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation plans for their executives.
- The vesting schedules and exercise prices are generally structured to encourage long-term commitment and value creation.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| January 1, 2024 | Date of grant for the restricted stock units (RSUs). |
| January 1, 2025 | Date of RSU vesting and stock option grant. |
| February 1, 2025 | Start date for monthly vesting of stock options. |
| January 1, 2028 | Final vesting date for the restricted stock units (RSUs). |
| January 1, 2029 | Final vesting date for the stock options. |
| January 3, 2025 | Date of Form 4 filing. |
| December 31, 2035 | Expiration date for the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.